Search research articles
Contact Us
Filters
Showing results (11-20 of 14) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 14 results.
Cancer Causes & Control : CCC
|
February 11, 2025
Prevalence of cannabis and medication use by indices of residential urbanicity and deprivation among Ohio cancer patients
Theodore M Brasky, Shieun Lee, Bella McBride, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
January 18, 2024
Current cannabis use and pain management among US cancer patients
Jessica L Krok-Schoen, Jesse J Plascak, Alison M Newton, et al.
Cancer Gene Therapy
|
March 23, 2021
Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer
Rodney P Rocconi, Erin E Stevens, Justin N Bottsford-Miller, et al.
The Lancet. Oncology
|
December 3, 2020
Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial
Rodney P Rocconi, Elizabeth A Grosen, Sharad A Ghamande, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 14) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 14 results.
Cancer Causes & Control : CCC
|
February 11, 2025
Prevalence of cannabis and medication use by indices of residential urbanicity and deprivation among Ohio cancer patients
Theodore M Brasky, Shieun Lee, Bella McBride, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
January 18, 2024
Current cannabis use and pain management among US cancer patients
Jessica L Krok-Schoen, Jesse J Plascak, Alison M Newton, et al.
Cancer Gene Therapy
|
March 23, 2021
Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer
Rodney P Rocconi, Erin E Stevens, Justin N Bottsford-Miller, et al.
The Lancet. Oncology
|
December 3, 2020
Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial
Rodney P Rocconi, Elizabeth A Grosen, Sharad A Ghamande, et al.
Page
of 2